• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for visual impairment in children younger than 6 years - rapid report]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stents for the treatment of intracranial artery stenosis: VISSIT study and acute treatment in Germany (working paper on commission N14-01)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of haemophilia patients - Rapid report]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafluprost/timolol (Addendum to Commission A14-49)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Testing of a method for assessing the internal validity of guideline recommendations, using the example of evidence-based guidelines on preoperative diagnostics]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (Addendum to Commission A15-07)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (addendum to commission A15-10)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Safinamide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib (Addendum to Commission A15-13)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lomitapide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-coated drug-eluting stents for treatment of coronary artery stenosis]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide (Addendum to Commission A15-15)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine (Addendum to Commission A15-16)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belatacept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Safinamide (Addendum to Commission A15-18)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab - Addendum to Commission A15-20]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Edoxaban - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Netupitant/palonosetron - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiotropium/olodaterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lomitapide - Addendum to Commission A15-23]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "chronic back pain"]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "chronic heart failure"]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belatacept: addendum to Commission A15-25]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab: addendum to Commission A15-27]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sebelipase alfa - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Panobinostat: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide: benefit assessment according to §35a Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regorafenib: benefit assessment according to §35a Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa (Addendum to commission E14-07)]
2015 Belgian Health Care Knowledge Centre (KCE) Percutaneous vertebroplasty and balloon kyphoplasty
2015 Belgian Health Care Knowledge Centre (KCE) Cervical and lumbar total disc replacements
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Tonsillectomy, adenoidectomy and adenotonsillectomy for obstructive sleep apnoea: review of clinical evidence and guidelines
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Hysteroscopy for abnormal uterine bleeding: review of clinical evidence and guidelines
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The RePneu Coil System and other bronchoscopic lung volume reduction treatments for advanced emphysema
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve blocking and gastric artery embolisation for obesity
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Barricaid prosthesis for partial annulus replacement
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) ZioPatch for diagnosis of cardiac arrhythmias
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) ROX Coupler for treatment-resistant hypertension
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) STAR tumour ablation system
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Microwave ablation for liver tumours
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) ViewRay System for MRI guided radiotherapy
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) InSpace biodegradable subacromial spacer for the treatment of rotator cuff tears
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Bioresorbable vascular scaffolds
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transcatheter mitral valve replacement for severe mitral regurgitation
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Optical coherence tomography (OCT) for retinal assessment in the presence of diabetic macular oedema (DMO) for access to treatment with dexamethasone posterior segment drug delivery system
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Intravascular ultrasound guided coronary stent insertion
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Intravascular ultrasound (IVUS) guided coronary stent insertion
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Local anaesthetic (LA) nerve blockade for post-surgical analgesia
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) MRI liver - scan for the detection and characterisation of focal liver lesions
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Shared medical appointments (SMAs) for type 2 diabetes management
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Orthotics and prosthetics workforce planning
2015 National Institute for Health and Care Excellence (NICE) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. NICE technology appraisal guidance 329
2015 National Institute for Health and Care Excellence (NICE) Sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance 330
2015 National Institute for Health and Care Excellence (NICE) Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. NICE technology appraisal guidance 333
2015 National Institute for Health and Care Excellence (NICE) Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal). NICE technology appraisal guidance 334
2015 National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. NICE technology appraisal guidance 335
2015 National Institute for Health and Care Excellence (NICE) Empagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 336
2015 National Institute for Health and Care Excellence (NICE) Rifaximin for preventing episodes of overt hepatic encephalopathy. NICE technology appraisal guidance 337
2015 National Institute for Health and Care Excellence (NICE) Omalizumab for previously treated chronic spontaneous urticaria. NICE technology appraisal guidance 339
2015 National Institute for Health and Care Excellence (NICE) Ustekinumab for treating active psoriatic arthritis. NICE technology appraisal guidance 340
2015 National Institute for Health and Care Excellence (NICE) Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 341
2015 National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 342
2015 National Institute for Health and Care Excellence (NICE) Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 343
2015 National Institute for Health and Care Excellence (NICE) Naloxegol for treating opioid-induced constipation. NICE technology appraisal guidance 345
2015 National Institute for Health and Care Excellence (NICE) Aflibercept for treating diabetic macular oedema. NICE technology appraisal guidance 346
2015 National Institute for Health and Care Excellence (NICE) Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE technology appraisal guidance 347
2015 National Institute for Health and Care Excellence (NICE) Everolimus for preventing organ rejection in liver transplantation. NICE technology appraisal guidance 348
2015 National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 350
2015 National Institute for Health and Care Excellence (NICE) Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of antiplatelet therapy (terminated appraisal). NICE technology appraisal guidance 351
2015 National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. NICE technology appraisal guidance 352
2015 National Institute for Health and Care Excellence (NICE) Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal). NICE technology appraisal guidance 353
2015 National Institute for Health and Care Excellence (NICE) Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 354
2015 National Institute for Health and Care Excellence (NICE) Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance 355